[HTML][HTML] Why are tumour blood vessels abnormal and why is it important to know?

JA Nagy, SH Chang, AM Dvorak, HF Dvorak�- British journal of cancer, 2009 - nature.com
Tumour blood vessels differ from their normal counterparts for reasons that have received
little attention. We report here that they are of at least six distinct types, we describe how�…

[HTML][HTML] Microtubule targeting agents in disease: classic drugs, novel roles

L Wordeman, JJ Vicente�- Cancers, 2021 - mdpi.com
Simple Summary Microtubules (MTs) are highly conserved proteins present in all eukaryotic
organisms. They form the cell cytoskeleton, and its function is essential for a large number of�…

Quinoline as a privileged scaffold in cancer drug discovery

VR Solomon, H Lee�- Current medicinal chemistry, 2011 - ingentaconnect.com
Quinoline (1-azanaphthalene) is a heterocyclic aromatic nitrogen compound characterized
by a double-ring structure that contains a benzene ring fused to pyridine at two adjacent�…

[BOOK][B] Anticancer agents from natural products

GM Cragg, DGI Kingston, DJ Newman - 2005 - taylorfrancis.com
Plants, marine organisms, and microorganisms have evolved complex chemical defense
and signaling systems that are designed to protect them from predators and provide other�…

Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning

P Vempati, AS Popel, F Mac Gabhann�- Cytokine & growth factor reviews, 2014 - Elsevier
The regulation of vascular endothelial growth factor A (VEGF) is critical to
neovascularization in numerous tissues under physiological and pathological conditions�…

Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells

TT Chen, A Luque, S Lee, SM Anderson…�- Journal of cell�…, 2010 - rupress.org
VEGF can be secreted in multiple isoforms with variable affinity for extracellular proteins and
different abilities to induce vascular morphogenesis, but the molecular mechanisms behind�…

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules

A Grothey, E Galanis�- Nature reviews Clinical oncology, 2009 - nature.com
Angiogenesis—one of the hallmarks of cancer—has emerged as a valid therapeutic target in
oncology. The VEGF system represents a key mediator of tumor-initiated angiogenesis and�…

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

J Ma, DJ Waxman�- Molecular cancer therapeutics, 2008 - AACR
Angiogenesis is a hallmark of tumor development and metastasis and is now a validated
target for cancer treatment. However, the survival benefits of antiangiogenic drugs have thus�…

Vascular disrupting agents in cancer therapy

R Smolarczyk, J Czapla, M Jarosz-Biej…�- European Journal of�…, 2021 - Elsevier
Tumor blood vessel formation is a key process for tumor expansion. Tumor vessels are
abnormal and differ from normal vessels in architecture and components. Besides oxygen�…

Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion

M Perrot-Applanat, M Di Benedetto�- Cell adhesion & migration, 2012 - Taylor & Francis
Vascular endothelial growth factor A (VEGF-A) is well known for its key roles in blood vessel
growth. Although most studies on VEGF and VEGF receptors have been focused on their�…